Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

A High-Throughput Drug Repurposing Strategy to Treat TBX2 and/or TBX3 Dependent Cancers.

Bleloch JS. et al, (2024), Cancer medicine, 13

Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors.

Kent D. et al, (2024), Hepatology (Baltimore, Md.)

Improving the representativeness of UK's national COVID-19 Infection Survey through spatio-temporal regression and post-stratification.

Pouwels KB. et al, (2024), Nature communications, 15

Targeting NKG2D ligands in glioblastoma with a bispecific T-cell engager is augmented with conventional therapy and enhances oncolytic virotherapy of glioma stem-like cells

Baugh R. et al, (2024), Journal for ImmunoTherapy of Cancer, 12, e008460 - e008460

Optimized protocol for CRISPR knockout of human iPSC-derived macrophages.

Navarro-Guerrero E. et al, (2024), STAR Protoc, 5

Author Correction: C16orf72/HAPSTR1/TAPR1 functions with BRCA1/Senataxin to modulate replication-associated R-loops and confer resistance to PARP disruption.

Sharma AB. et al, (2023), Nature communications, 14

Persistence of SARS-CoV-2 antibodies over 18 months following infection: UK Biobank COVID-19 Serology Study.

Bešević J. et al, (2023), Journal of epidemiology and community health

Selective ROCK Inhibitor Enhances Blood Flow Recovery after Hindlimb Ischemia

Fayed HS. et al, (2023), International Journal of Molecular Sciences, 24, 14410 - 14410

Chemogenomic library design strategies for precision oncology, applied to phenotypic profiling of glioblastoma patient cells

Athanasiadis P. et al, (2023), iScience, 26

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK

Buckell J. et al, (2023), Scientific Reports, 13

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Wei J. et al, (2023), Nature Communications, 14

Data from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023), Clinical Cancer Research, 29, 1631 - 1642

Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Supplementary Figure S1 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Supplementary Figure S2 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Supplementary Figure S3 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Supplementary Figure S4 from Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models

Rodriguez-Berriguete G. et al, (2023)

Load More

1
2
3
4
5
6

Include forthcoming?